50 completed, 11 recruiting, 9 terminated, 9 unknown. 54 Phase 2, 24 Phase 1, 13 Phase 3, 6 Not applicable.
Follow Histiocytoma, Malignant Fibrous: new trials by email Literature Review of Histiocytoma, Malignant Fibrous trials Research Report on Histiocytoma, Malignant Fibrous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma DT-7012, Doxorubicin - Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS) | Phase 2 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 80 | 2027-02-01 | 2026-09-15 |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma Lifileucel - Sarcoma, Soft Tissue Sarcoma (STS) | Phase 2 | Recruiting | Iovance Biotherapeutics, Inc. | 80 | 2026-10-02 | 2026-10-09 |
| SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic Sarcoma Toripalimab, Liposomal doxorubicin, Stereotactic body radiotherapy (SBRT) - Undifferentiated Pleomorphic Sarcoma (UPS) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 39 | 2026-09-01 | 2026-09-14 |
| Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2026-01-26 | 2026-01-28 |
| Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma preoperative, Quality of life, Functional outcome - Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 110 | 2026-01-26 | 2026-01-28 |
| Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma Biopsy, Chest Computed Tomography, Chest Radiography - Adult Pleomorphic Rhabdomyosarcoma, AJCC Grade 2 Sarcoma | Not applicable | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 1582 | 2025-01-28 | 2024-07-30 |
| A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors OKN4395, Pembrolizumab, Fasting - Solid Tumours, Sarcoma | Phase 1 | Recruiting | Epkin | 146 | 2025-01-23 | 2026-06-11 |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin - Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 365 | 2024-09-11 | 2026-10-22 |
| Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma Brigimadlin, Ezabenlimab, Gemcitabine - Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS) | Phase 3 | Withdrawn | Boehringer Ingelheim | 2024-06-27 | 2024-07-17 | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-02-06 | 2026-10-22 |
| Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma Biopsy Procedure, Biospecimen Collection, Cabozantinib - Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma | Phase 2 | Active not recruiting | National Cancer Institute LAO | 66 | 2023-10-25 | 2026-10-09 |
| Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications BBI-355, Erlotinib, Futibatinib - Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma | Phase 1 | Terminated | Boundless Bio, Inc. | 85 | 2023-03-24 | 2026-08-19 |
| Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas Osteosarcoma, Bone Tumor | Not yet recruiting | Klinikum Stuttgart | 1000 | 2022-09-01 | 2022-08-25 | |
| Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas Association of pembrolizumab + cabozantinib - Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma | Phase 2 | Recruiting | Institut Bergonié | 119 | 2022-04-25 | 2025-10-07 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients Propranolol, Pembrolizumab - Soft Tissue Sarcoma Adult, Angiosarcoma | Phase 2 | Recruiting | Niels Junker | 80 | 2021-08-17 | 2023-07-27 |
| Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study Sintilimab - Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2021-07-13 | 2024-12-11 |
| ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Envafolimab, Ipilimumab - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 2 | Unknown | Tracon Pharmaceuticals Inc. | 207 | 2020-12-09 | 2024-05-17 |
Showing 20 of 91. Sign in to see all of them.
Sarcoma (72) · Leiomyosarcoma (61) · Liposarcoma (55) · Sarcoma, Synovial (49) · Fibrosarcoma (42) · Neurofibrosarcoma (41) · Hemangiosarcoma (39) · Dermatofibrosarcoma (26) · Rhabdomyosarcoma (25) · Sarcoma, Alveolar Soft Part (23) · Hemangiopericytoma, Malignant (20) · Malignant mesenchymal tumor (18) · Osteosarcoma (15) · Chondrosarcoma, Extraskeletal Myxoid (14)
Neoplasms by Histologic Type (91) · Neoplasms, Connective Tissue (91) · Neoplasms, Fibrous Tissue (91) · Neoplasms, Connective and Soft Tissue (90) · Histiocytoma (88) · Neoplasms (85) · Neoplasms, Muscle Tissue (63) · Neoplasms, Adipose Tissue (56) · Neoplasms, Nerve Tissue (46) · Nervous System Diseases (43) · Nervous System Neoplasms (43) · Peripheral Nervous System Neoplasms (42) · Neoplasms, Vascular Tissue (41) · Neurofibroma (41) · Neuromuscular Diseases (41)
Doxorubicin (20) · Ifosfamide (12) · Radiotherapy (11) · Ipilimumab (6) · Nivolumab (6) · pembrolizumab (6) · Biopsy (4) · CTLA-4 Antigen (4) · Docetaxel (4) · Gemcitabine (4) · Radiation (4) · Specimen Handling (4) · pazopanib (4) · Magnetic Resonance Spectroscopy (3) · Sunitinib (3)
European Organisation for Research and Treatment of Cancer - EORTC (15) · National Cancer Institute (NCI) (14) · M.D. Anderson Cancer Center (4) · Memorial Sloan Kettering Cancer Center (4) · Brown University (2) · Eli Lilly and Company (2) · Institut Bergonié (2) · Maria Sklodowska-Curie National Research Institute of Oncology (2) · OHSU Knight Cancer Institute (2) · Oslo University Hospital (2) · AbbVie (1) · Alliance for Clinical Trials in Oncology (1) · BioAtla, Inc. (1) · Boehringer Ingelheim (1) · Boundless Bio, Inc. (1)
United States (55) · France (14) · United Kingdom (14) · Canada (12) · Belgium (11) · Denmark (10) · Germany (10) · Netherlands (10) · Spain (9) · Poland (6) · Slovakia (5) · Switzerland (5) · Austria (4) · Italy (4) · Norway (4)
Ivar Hompland, MD, PhD (2) · Kjetil Boye, MD, PhD (2) · A P Chen (1) · A.N. Van Geel, MD (1) · Aaron H. Wolfson, MD (1) · Aaron R Weiss (1) · Alba Rubio (1) · Alberto Chiappori, M.D. (1) · Allan T. van Oosterom, MD, PhD (1) · Amir A Jazaeri (1) · Antonio Casado (1)
PMID 31401903, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17109446, PMID 17336054, PMID 17634494, PMID 19088049, PMID 19451429, PMID 20434400, PMID 20471824, PMID 22954508, PMID 23382028, PMID 23640206, PMID 24215845, PMID 24618336, PMID 24637635, PMID 24747207, PMID 25858498, PMID 27502708, PMID 28391003, PMID 28447475, PMID 29370992, PMID 29450452, PMID 30249211, PMID 30410720, PMID 30954717, PMID 31786124, PMID 32259228, PMID 32702309, PMID 32827353, PMID 32941794, PMID 33203665, PMID 33548339, PMID 33632930, PMID 34515544, PMID 34623899, PMID 34666214, PMID 34722269, PMID 35115306, PMID 35260879, PMID 35934010, PMID 36566574, PMID 37523624
P30CA008748 (3), U10CA180821 (3), 2015 (2), N01CM62206 (2), U10CA098543 (2), UM1CA186709 (2), 2009 (1), K08CA245181 (1), N01CM00071 (1), N01CM62201 (1), N01CM62203 (1), P30CA012197 (1), P30CA014599 (1), P30CA033572 (1), U01CA069856 (1)